Status:

UNKNOWN

Observation Study With Implantable Medication Pump for Intravenous Treprostinil Therapy in Patients With Pulmonary Arterial Hypertension

Lead Sponsor:

University Medicine Greifswald

Collaborating Sponsors:

OMT GmbH & Co. KG

Conditions:

Pulmonary Arterial Hypertension

PAH

Eligibility:

All Genders

18+ years

Brief Summary

The study is designed as a non-interventional, multicenter, prospective single-arm study to observe the therapy with REMODULIN (Treprostinil) applicated by an implantable pump in patients with pulmona...

Detailed Description

Patients that suffer from progressing PAH are medicated with intravenous prostanoids since the 80's of the last century. Nowadays, specific treatment of PAH can be realized by the huge number of subst...

Eligibility Criteria

Inclusion

  • diagnosis of pulmonary arterial hypertension (WHO group I) accordingly to international guidelines
  • intermediate or high risk-profile of PAH after at least three months treatment with vasoactive substances including Selexipag
  • indication of intravenous therapy with Treprostinil
  • informed consent given for implantation of the medical pump LENUS pro
  • informed consent given for participation in the LPS-II study

Exclusion

  • contraindications according to package information leaflet (LENUS pro) and/or summary of product characteristics (Treprostinil)
  • Patient is diagnosed with PAH with an etiology different from that of the inclusion criteria
  • chronic kidney insufficiency (estimated GFR \< 30)
  • hepatic insufficiency: CHILD C (known information from patients medical records)
  • intake of substances with potential for infections: intravenous drug abuse, prednisolone, azathioprine, cyclophosphamide
  • suffering from diseases with potential for infections: immunodeficiency syndrome, diabetes mellitus, diabetic gangrene
  • pregnant or breastfeeding women
  • women of childbearing potential who are not on a reliable and safe form of contraception

Key Trial Info

Start Date :

March 1 2020

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 1 2021

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT04309838

Start Date

March 1 2020

End Date

December 1 2021

Last Update

March 16 2020

Active Locations (8)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (8 locations)

1

DRK Kliniken Berlin Westend

Berlin, Germany, 14050

2

Uniklinik Köln

Cologne, Germany, 50937

3

Universitätsklinikum Gießen

Giessen, Germany, 35392

4

Universitätsmedizin Greifswald

Greifswald, Germany, 17489